Viatris Inc. (VTRS)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Viatris Inc. (“Viatris” or “the Company”) (NASDAQ: VTRS). Investors who purchased Viatris securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Viatris has violated federal securities laws.
Investigation Details
On February 27, 2025, Viatris issued a press release reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics. In addition, Viatris provided lower-than-expected full-year guidance for 2025. Viatris also provided an update on remediation work at a manufacturing facility in India following receipt of a warning letter and import alert from the U.S. Food and Drug Administration, advising that it was “more than halfway through its remediation efforts and expects to be completed in a few months at which time the Company anticipates requesting FDA to conduct a reinspection of the facility.” On this news, Viatris’s stock price fell $1.71 per share, or 15.21%, to close at $9.53 per share on February 27, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Viatris securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com